An Observational Study of Treatment, Outcomes, and Prognosis in Patients With Follicular Non-Hodgkin's Lymphoma
Completed
- Conditions
- Lymphoma, Non Hodgkin
- Registration Number
- NCT00097565
- Lead Sponsor
- Genentech, Inc.
- Brief Summary
This is a prospective, observational, longitudinal, multicenter study of patients with newly diagnosed follicular Non Hodgkin's Lymphoma (NHL) designed to delineate differences in clinical outcome by comparing the effectiveness and safety of common treatment regimens.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 2740
Inclusion Criteria
- Signed Informed Consent Form (unless the Institutional Review Board [IRB] has granted a waiver of consent)
- Signed Authorization for the Use and Disclosure of Health Information document
- Age ≥18 years
- Histologic documentation of follicular NHL, according to Revised European-American Lymphoma (REAL) classification system, as assessed by the local pathologist and treating physician
- Initial diagnosis of follicular B-cell NHL within 6 months prior to enrollment
- Availability of cancer-specific historical data points in the patient's medical records
Exclusion Criteria
- Other indolent or histologic NHL subtypes
- Diagnosis of lymphoma > 6 months prior to enrollment
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie treatment response in follicular lymphoma patients enrolled in NCT00097565?
How does rituximab-based therapy compare to standard-of-care regimens in follicular NHL outcomes per NCT00097565?
Which biomarkers correlate with prognosis in follicular lymphoma as identified by the National Lymphocare Study?
What adverse events are associated with follicular lymphoma treatments in NCT00097565 and how are they managed?
How do BTK inhibitors or other targeted therapies compare to observational data from NCT00097565 in follicular NHL?